Conceptus Inc

Conceptus — Q2 2011 Earnings Presentation

34 slides from Conceptus's earnings presentation, Aug 4, 2011

  1. Slide 1: Conceptus, Inc. Quarterly Results Second Quarter of 2011

    Exhibit 99.2 Conceptus, Inc. Quarterly Results Second Quarter of 2011 August 4, 2011 © 2011 Conceptus, Inc. All rights reserved.

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements, the accuracy of which is subject to risks and uncertainties. These forward- looking statements include discussions regarding: projected net sales and adj

  3. Slide 3: Q2'11 Highlights

    Q2’11 Highlights Mark Sieczkarek, President and Chief Executive Officer © 2011 Conceptus, Inc. All rights reserved.

  4. Slide 4: Progress on Execution

    Progress on Execution Key areas of focus in 2011: 1. 2. 3. Defend against Create Resume competitive foundation to expanding the trialing increase market for Essure Essure utilization POSITION FOR LONG-TERM GROWTH Macro-economy: continuing unemployment and higher insurance premiums, deductible and co

  5. Slide 5: OB/GYN Office Visit Trends

    OB/GYN Office Visit Trends OB/GYN office visits improved Q/Q OB/GYN Patient office visits in millions % change in select periods: Period: OB/GYN 2010 vs 2009 -15% 2 Years: Q2’11 -20% vs Q2’09 1 Year: Q2’11 -2% vs Q2’10 Sequential: Q2’11 9% vs Q1’11 Source: IMS data provided by Credit Suisse Healthca

  6. Slide 6: Market Growth Trends

    Market Growth Trends Worldwide hysteroscopic sterilization market declined slightly Y/Y in Q2’11 but improved Q/Q In $ millions Q3 09 Q4 09 Q1 10 Q2 10(1) Q3 10 Q4 10 Q1 11 Q2 11 Total CPTS Sales $34.2 $37.0 $33.4 $36.8 $33.9 $36.5 $26.6 $33.8 Competitor’s $5.6 - Estimated $0.6 $1.5 $2.1 $3.8 $5.2 $

  7. Slide 7: Competitive Trialing Declines

    Competitive Trialing Declines We continue to successfully defend our accounts In total ~500 accounts were covered by 1-3 Number of Essure accounts that entered competitive trialing by quarter year Essure preferred vendor agreements by the end of Q2’11 Sales Force ~1,300 accounts have trialed to date

  8. Slide 8: Market Share Stable

    Market Share Stable Worldwide hysteroscopic sterilization market: Conceptus remains market leader In $ millions Q3 09 Q4 09 Q1 10 Q2 10(1) Q3 10 Q4 10 Q1 11 Q2 11 Total CPTS Sales $34.2 $37.0 $33.4 $36.8 $33.9 $36.5 $26.6 $33.8 Competitor’s $5.6 - Estimated $0.6 $1.5 $2.1 $3.8 $5.2 $5.3 $5.3 $5.8 Sa

  9. Slide 9: Increase Essure Utilization

    Increase Essure Utilization Essure = medically necessary link between PBC(1) and GEA Capture share of in-office GYNECARE THERMACHOICE®III(2) patients requiring PBC to potentially double annual market for Essure GYNECARE Incremental THERMACHOICE ® III Essure Procedures Physician trials >2,000 physici

  10. Slide 10: Marketing To Drive Growth

    Marketing To Drive Growth Further develop key marketing strategies to increase adoption of Essure and drive long-term growth Physician Segmentation Consumer Segmentation Target underpenetrated Own unique in-office sales franchise U.S. market for Essure of 9.3M women(1) Publication Planning Direct-to

  11. Slide 11: Integrate Value Proposition

    Integrate Value Proposition Integrate patient and physician value proposition to increase Essure utilization at point of care Point of Consumer Physician Care • New Essurance Promise™ • Patient support and • Resident, new-user and in- Program counseling through office training • New Essure FlexPay™

  12. Slide 12: Direct-to-Consumer Planned

    Direct-to-Consumer Planned Launch new DTC marketing campaign in Q3’11 Build upon our previous DTC experience Leverage experience in temporary birth control advertising National focus Invest resources across the most cost-effective mediums Segment potential patient base and target message accordingly

  13. Slide 13: Q2'11 Financials

    Q2’11 Financials Greg Lichtwardt Executive Vice President, Operations and Chief Financial Officer © 2011 Conceptus, Inc. All rights reserved.

  14. Slide 14: Q2'11 Snapshot

    Q2’11 Snapshot Net Sales Gross Margin Operating Adj. EBITDA(1) Diluted GAAP ($M) (%) Exp. ($M) ($M) EPS $36.8 81.9% 80.2% $33.8 $28.1 $25.8 $5.2 $5.8 $0.01 ($0.01) Q2’10 Q2’11 Q2’10 Q2’11 Q2’10 Q2’11 Q2’10 Q2’11 Q2’10 Q2’11 (1) Adjusted earnings before interest, taxes, depreciation, amortization and

  15. Slide 15: Worldwide Sales

    Worldwide Sales Q2’11 Net Sales (in $ millions) Q2’11 Units (in thousands): $36.8 33.3 $33.8 29.4 $8.9 13.2 (24%) $9.0 (40%) 11.6 (27%) (39%) $28.0 $24.8 (76%) (73%) 20.1 (60%) 17.8 (61%) Q2’10 Q2’11 Q2’10 Q2’11 Domestic International Columns may not add due to rounding 15 © 2011 Conceptus, Inc. All

  16. Slide 16: Physician Metrics Pipeline Grew

    Physician Metrics Pipeline Grew We returned to expanding the market for Essure in Q2’11 Q2’11 Q1’11(1) Q4’10(1) Q3’10(1) Q2’10(1) Current Period Activity: Physicians entering preceptorship 538 388 380 380 425 Physicians becoming certified 290 200 427 334 368 Physicians transitioning to in-office 110

  17. Slide 17: Q2'11 Highlights

    Q2’11 Highlights In $ millions except for EPS (1) Adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation. See appendix. (2) Net loss after taxes includes a net income tax benefit of $2.3 million. 17 © 2011 Conceptus, Inc. All rights reserved.

  18. Slide 18: Q2'11 Adjusted EBITDA

    Q2’11 Adjusted EBITDA $ millions $1.39 $5.85 $1.73 $0.82 $1.63 ($0.17) $0.45 Net income Interest Benefit Amortization Stock- Depreciation Adjusted and other from of based expense EBITDA income income intangibles compensation (expense) taxes net See reconciliation in appendix 18 © 2011 Conceptus, Inc

  19. Slide 19: Balance Sheet

    Balance Sheet $ millions LIABILITIES & ASSETS 6/30/11 12/31/10 EQUITY 6/30/11 12/31/10 Cash & cash equivalents 25.8 18.4 A/P & other accrued ST liabilities 17.0 15.8 Investments 69.8 72.5 Notes payable(1) 83.3 81.0 Accounts receivable 19.6 20.4 Other accrued LT liabilities 2.5 2.4 Inventories & othe

  20. Slide 20: Guidance

    Guidance FY’11E FY’10 as of 8/4/11 Actual $135M to Net Sales $141M $140M 81.9% to Gross Profit Margin 80.9% 82.2% Operating $103M to $104M Expenses $105M $23M to Adjusted EBITDA(1) $25M $26M (1) See appendix 20 © 2011 Conceptus, Inc. All rights reserved.

  21. Slide 21: 2011: Strategic Plan Update

    2011: Strategic Plan Update Mark Sieczkarek, President and Chief Executive Officer © 2011 Conceptus, Inc. All rights reserved.

  22. Slide 22: Strategic Plan Goals

    Strategic Plan Goals We remain committed to our strategic plan to drive long- term revenue growth across the world Goals Environment Response •Navigate current •Challenging macroeconomic and •Continue to execute our economy and insurance trends continue strategic plan and control make Essure what we

  23. Slide 23: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 1. Minimize •Defend our existing accounts •Expanded sales force impact of against competitive trialing competition •Continue to educate and gain back •Filed with FDA to remove physicians on Essure’s contraindication of nickel superior efficacy market sha

  24. Slide 24: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 2. Increase •Leverage in-office channel •Launched GYNECARE Essure strength to promote THERMACHOICE ® III promotion utilization GYNECARE THERMACHOICE ® efforts in Q1’11 III to U.S. physician offices •>2,000 physicians have •PBC is medically necessary for

  25. Slide 25: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 3. Drive •Growth strategies include •Expanded marketing adoption of physician and consumer organization now in place Essure through segmentation, owning the strategic, in-office sales process, •Launched Essure FlexPayTM Plan to make patient integrated pu

  26. Slide 26: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 4. Expand •Europe •Europe: have launched international targeted PR campaigns in presence •France various countries •U.K. •France: working to reinstate •Brazil reimbursement for <40 market; increased targeting of 40 •Emerging markets market •U.K.: in disc

  27. Slide 27: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 5. Washington •Include contraception under •HHS mandated inclusion of DC focus and the PPACA guidelines permanent birth control under reimbursement PPACA at no cost to patients – issues •Medicaid reimbursement and represents a key inflection cost saving

  28. Slide 28: Strategic Plan Update

    Strategic Plan Update Strategy Details Status 6. Create a •Designed to accelerate •Ongoing review of potential pipeline of adoption of Essure high-growth synergistic women’s opportunities health products •Provide more diversified offerings •Prefer in-office setting and services 7. Product •Develop n

  29. Slide 29: Key Take-Aways

    Key Take-Aways We are dedicated to making Essure the “Standard of Care” in the PBC market, even as macroeconomic and insurance challenges remain The competitive threat appears to be stabilized and we will sharpen our focus on increasing utilization and growing the market for Essure Strategic marketi

  30. Slide 30: Appendix

    Appendix © 2011 Conceptus, Inc. All rights reserved.

  31. Slide 31: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures The Company has supplemented its GAAP net income / (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation (“adjusted EBITDA”). Management believes that this non-GAAP financial measure prov

  32. Slide 32: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Conceptus, Inc. Reconciliation of Net Income (loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) (Unaudited) (In thousands) Three Months Ended Six Months Ended June 30, June 30, 2011 2010 2011 2

  33. Slide 33: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Conceptus, Inc. Reconciliation of Forward-Looking Guidance For Non-GAAP Financial Measures To Projected GAAP Net Income (Unaudited) Twelve Months Ending December 31, 2011 From To Net Income Guidance $ 560 $ 2,297 Estimated Non-GAAP Guidance Interest and other income (

  34. Slide 34: Conceptus, Inc.

    Conceptus, Inc. NASDAQ: CPTS Revolutionizing women’s healthcare with innovative solutions CC-2847 4AUG11F © 2011 Conceptus, Inc. All rights reserved.

Conceptus — Q2 2011 Earnings Presentation on 6ix